Corvus Pharmaceuticals (CRVS) News Today $3.93 -0.32 (-7.53%) Closing price 04:00 PM EasternExtended Trading$3.90 -0.03 (-0.76%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call TranscriptMarch 25 at 9:01 PM | seekingalpha.comCorvus Pharmaceuticals outlines clinical milestones for soquelitinib in 2025March 25 at 9:00 PM | msn.comCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 25 at 4:01 PM | globenewswire.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives $12.38 Average PT from AnalystsMarch 23 at 2:09 AM | americanbankingnews.comCorvus shares progress on soquelitinib in T cell lymphoma trialMarch 22 at 9:24 PM | uk.investing.comCorvus announces presentation of data from Phase 1/1b trial of soquelitinibMarch 22 at 7:30 AM | markets.businessinsider.comCorvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell LymphomaMarch 20, 2025 | globenewswire.comCorvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 19, 2025 | globenewswire.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Buy" from AnalystsCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) has received a consensus recommendation of "Buy" from the five analysts that are presently covering the stock, MarketBeat reports. Four analysts have rated the stock with a buy recommendation and one has given a strong buy recommendationMarch 18, 2025 | marketbeat.comCorvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025March 17, 2025 | globenewswire.comCorvus Pharmaceuticals (CRVS) to Release Quarterly Earnings on TuesdayMarch 16, 2025 | americanbankingnews.comCorvus Pharmaceuticals announces initiation of Phase 2 trial of soquelitinibMarch 12, 2025 | markets.businessinsider.comCorvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)March 12, 2025 | globenewswire.comCorvus Pharmaceuticals (CRVS) to Release Earnings on TuesdayCorvus Pharmaceuticals (NASDAQ:CRVS) will be releasing earnings before the market opens on Tuesday, March 18, Financial Modeling Prep reports.March 11, 2025 | marketbeat.comCorvus Pharmaceuticals: Small Market, Many Competitors, Low Cash BalanceMarch 3, 2025 | seekingalpha.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Buy" by AnalystsShares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been given a consensus recommendation of "Buy" by the five analysts that are covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy rating and one has given a strongFebruary 21, 2025 | marketbeat.comCorvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 4, 2025 | globenewswire.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Buy" from BrokeragesShares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have earned an average recommendation of "Buy" from the five research firms that are covering the company, Marketbeat reports. Four research analysts have rated the stock with a buy recommendation and one has assigned a strongJanuary 27, 2025 | marketbeat.comCantor Fitzgerald Forecasts CRVS FY2025 EarningsCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Corvus Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings ofJanuary 22, 2025 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $11.00 target price on shares of Corvus Pharmaceuticals in a research note on Tuesday.January 14, 2025 | marketbeat.comCorvus announces data from cohort 2 of Phase 1 trial of SoquelitinibJanuary 14, 2025 | markets.businessinsider.comCorvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisJanuary 13, 2025 | globenewswire.comGeode Capital Management LLC Increases Stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Geode Capital Management LLC boosted its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 22.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 563,009 sharJanuary 8, 2025 | marketbeat.comCorvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | globenewswire.comWe're Not Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash BurnJanuary 7, 2025 | finance.yahoo.comWhat is HC Wainwright's Forecast for CRVS FY2024 Earnings?Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Equities research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a report released on Thursday, January 2nd. HC Wainwright analyst S. Lee expects that the company wJanuary 6, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for CRVS Q4 Earnings?Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Stock analysts at HC Wainwright issued their Q4 2024 EPS estimates for Corvus Pharmaceuticals in a research report issued on Thursday, January 2nd. HC Wainwright analyst S. Lee forecasts that the company will post earnings per share of ($January 3, 2025 | marketbeat.comCorvus Pharmaceuticals initiated with a Buy at H.C. WainwrightJanuary 3, 2025 | markets.businessinsider.comCorvus wins new buy from H.C. Wainwright despite recent selloffJanuary 3, 2025 | msn.comHC Wainwright & Co. Initiates Coverage of Corvus Pharmaceuticals (CRVS) with Buy RecommendationJanuary 3, 2025 | msn.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Buy" from AnalystsShares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been given a consensus recommendation of "Buy" by the four analysts that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a buy recommendation and one has given a strong buy recommenJanuary 2, 2025 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Now Covered by Analysts at HC WainwrightHC Wainwright initiated coverage on Corvus Pharmaceuticals in a research report on Thursday. They set a "buy" rating and a $11.00 price target on the stock.January 2, 2025 | marketbeat.comMizuho Securities Sticks to Their Buy Rating for Corvus Pharmaceuticals (CRVS)December 20, 2024 | markets.businessinsider.comCorvus: Early Atopic Dermatitis Data Signals More Questions Than Answers (Rating Downgrade)December 19, 2024 | seekingalpha.comCorvus Pharmaceuticals announce interim data from Phase 1 trial of soquelitinibDecember 18, 2024 | markets.businessinsider.comCorvus falls after early-stage data for eczema therapyDecember 18, 2024 | msn.comCorvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor TargetingDecember 18, 2024 | seekingalpha.comCorvus Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:CRVS)Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) saw unusually large options trading on Wednesday. Investors acquired 5,716 put options on the stock. This is an increase of 264% compared to the typical daily volume of 1,570 put options.December 18, 2024 | marketbeat.comCorvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisDecember 18, 2024 | globenewswire.comCorvus Pharmaceuticals Shares Rise 14% Ahead of Soquelitinib Trial Data RevealDecember 18, 2024 | marketwatch.comCorvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024December 17, 2024 | globenewswire.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Sees Large Increase in Short InterestCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) was the target of a significant growth in short interest in November. As of November 30th, there was short interest totalling 3,510,000 shares, a growth of 6.4% from the November 15th total of 3,300,000 shares. Based on an average trading volume of 771,600 shares, the days-to-cover ratio is presently 4.5 days.December 17, 2024 | marketbeat.comIndividual investors account for 50% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while private equity firms account for 16%December 11, 2024 | sg.finance.yahoo.comPoint72 Asset Management L.P. Has $29.37 Million Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Point72 Asset Management L.P. trimmed its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 6.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,562,729 shares of the compDecember 6, 2024 | marketbeat.comCorvus publishes data on potential of soquelitinib to modulate tumor activityDecember 5, 2024 | markets.businessinsider.comConnor Clark & Lunn Investment Management Ltd. Has $724,000 Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)Connor Clark & Lunn Investment Management Ltd. raised its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 64.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 137,031 shaNovember 29, 2024 | marketbeat.comFY2024 EPS Estimates for CRVS Decreased by Cantor FitzgeraldCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst L. Watsek now anticipates thatNovember 18, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Sees Unusually-High Trading Volume - What's Next?Corvus Pharmaceuticals (NASDAQ:CRVS) Sees Strong Trading Volume - Here's What HappenedNovember 15, 2024 | marketbeat.comAn Intrinsic Calculation For Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Suggests It's 41% UndervaluedNovember 14, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Sold by Towerview LLCTowerview LLC decreased its holdings in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 70.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 117,500 shares of the company's stock aftNovember 14, 2024 | marketbeat.com Remove Ads Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVS Media Mentions By Week CRVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRVS News Sentiment▼0.210.68▲Average Medical News Sentiment CRVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRVS Articles This Week▼82▲CRVS Articles Average Week Remove Ads Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Enliven Therapeutics News Mineralys Therapeutics News Nurix Therapeutics News Vir Biotechnology News Intellia Therapeutics News Collegium Pharmaceutical News Arcus Biosciences News Rocket Pharmaceuticals News Xencor News Zymeworks News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRVS) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
